Reboxetine plus citalopram for refractory depression not responding to venlafaxine: Possible mechanisms

Psychopharmacology

Volumn 153, Issue 4, 2001, Pages 497-498

  Dursun, S M ^a   Devarajan, S ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; MONOAMINE OXIDASE INHIBITOR; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGED; CLINICAL ARTICLE; DEPRESSION; DOSE TIME EFFECT RELATION; DRUG MECHANISM; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; PRIORITY JOURNAL; RATING SCALE; SWEATING;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES;

EID: 0035102341     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130000579     Document Type: Letter

References (7)

1. Pharmacological strategies for refractory depression
2. Pharmacological management of treatment resistant depression
3. Citalopram plus reboxetine in treatment-resistant depression
4. Treatment resistant depression: Methological overview and operational criteria
5. Treatment-resistant depression: Progress and limitations
6. Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine